Nasus Pharma Announces Pricing of $15.0 Million Private Placement

Core Viewpoint - Nasus Pharma Ltd. has announced a private placement of ordinary shares and warrants, aiming to raise approximately $15.0 million to support its clinical development efforts and other corporate purposes [1][5]. Group 1: Private Placement Details - The private placement involves the sale of 2,695,425 ordinary shares and accompanying warrants, priced at $5.565 per share and warrant [3]. - The warrants will have an exercise price of $6.53 per share, are immediately exercisable, and will expire two years from issuance or 30 trading days after the announcement of NS002 pivotal study results [4]. - Citizens Capital Markets is the lead placement agent, with Laidlaw & Company (UK) Ltd. as the co-placement agent [2]. Group 2: Use of Proceeds - The net proceeds from the private placement will be used to advance the pivotal clinical development of NS002 for anaphylaxis treatment, initiate first-in-human studies for other products, and for working capital and general corporate purposes [5]. Group 3: Company Overview - Nasus Pharma is a clinical-stage pharmaceutical company focused on developing innovative intranasal products, particularly NS002, which is designed as a needle-free alternative for anaphylaxis treatment [8]. - The company's proprietary powder-based intranasal technology aims for rapid and reliable drug delivery, leveraging the nasal cavity's vascular network for quick absorption [8].